Floatz logo

Shr-9839

Advanced Malignant Tumour

Shandong Suncadia Medicine Co., Ltd.Phase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

1411 Active assets in the Advanced Malignant Tumour cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
Inno-206
M.D. Anderson Cancer Center
Phase 2BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB

View all 50 →

Same molecule, other indications

Shr-9839 is also rated in:

Advanced Solid TumorsDormant
CCC
Indicative ·
54 / 100
View asset →
Advanced KRAS G12D Mutant Solid TumorsDormant
CC
Indicative ·
47 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →